terlipressin (Terlivaz) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.   Wikipedia

Chemistry

  • SMILES: NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
  • InChIKey: BENFXAYNYRLAIU-QSVFAHTRSA-N
  • Mol. Mass: 1227.4
  • ALogP: Missing data
  • ChEMBL Molecule:
    terlipressin  
More Chemistry

Pharmacology

Alternative names

glipressin | glycylpressin | gly-gly-gly-8-lys-vasopressin | glypressin | n-(alpha)-glycyl-glycyl-glycyl-8-lysine vasopressin | n-(n- (n-glycylglycyl)glycyl)-8-l-lysinevasopressin | remestyp | terlipressin | terlipressina | terlipressin acetate | terlipressine | terlipressinum | terlypressin | tglvp | triglycyl-(8-lysine)vasopressin | triglycyl-8-lysine-vasopressin | triglycyl lysine vasopressin | triglycylvasopressin | variquel | vasopressin, tri-gly-8-lys-

Organizations (75)

Research & Development (74)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (2)


 

Hepatorenal Syndrome (approved 2022)

Renal Insufficiency

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Acute Kidney Injury (Phase 4)

Ascites (Phase 3)

Blood Loss, Surgical (Phase 2)

Blood Pressure (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Endoscopy (Phase 3)

Esophageal and Gastric Varices (Phase 4)

Fibrosis (Phase 4)

Hematemesis (Phase 4)

Hemodynamics (Phase 2)

Hemoptysis (Phase 3)

Hemorrhage (Phase 4)

Hepatorenal Syndrome (Phase 4)

Hypertension, Portal (Phase 4)

Intestinal Neoplasms (Phase 4)

Kidney Diseases (Phase 4)

Lipocalins (Phase 4)

Liver (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Failure (Phase 3)

Liver Transplantation (Phase 4)

Melena (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 3)

Renal Insufficiency (Phase 2)

Sepsis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 4)

Terlipressin (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 75
  • # of Trial Organizations: 74

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue